Experimental and clinical effects of isradipine relevant to atherosclerosis

F. Bernini, M. R. Soma, A. Corsini, R. Paoletti

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A number of studies in experimental animal models have demonstrated the potential direct antiatherosclerotic effects of calcium antagonists. This class of compounds can influence several processes that are involved in the development of atherosclerotic lesions. This action is independent of either blood pressure reduction or hypercholesterolemia. A major problem encountered from the experimental data are the high doses used, which are several times higher than those used in the treatment of humans. One notable exception to this problem is the second-generation calcium antagonist isradipine, which exerts a direct antiatherosclerotic effect in rabbits at doses similar to those used in the clinic. Thus, this review is a summary of the effects and mechanisms of the antiatherosclerotic activity of isradipine.

Original languageEnglish
Pages (from-to)30-34
Number of pages5
JournalAmerican Journal of Hypertension
Volume7
Issue number7 PART 2
Publication statusPublished - Jul 1994

Fingerprint

Isradipine
Atherosclerosis
Calcium
Hypercholesterolemia
Animal Models
Rabbits
Blood Pressure

Keywords

  • atherogenesis
  • atherosclerosis
  • calcium antagonists
  • Isradipine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Bernini, F., Soma, M. R., Corsini, A., & Paoletti, R. (1994). Experimental and clinical effects of isradipine relevant to atherosclerosis. American Journal of Hypertension, 7(7 PART 2), 30-34.

Experimental and clinical effects of isradipine relevant to atherosclerosis. / Bernini, F.; Soma, M. R.; Corsini, A.; Paoletti, R.

In: American Journal of Hypertension, Vol. 7, No. 7 PART 2, 07.1994, p. 30-34.

Research output: Contribution to journalArticle

Bernini, F, Soma, MR, Corsini, A & Paoletti, R 1994, 'Experimental and clinical effects of isradipine relevant to atherosclerosis', American Journal of Hypertension, vol. 7, no. 7 PART 2, pp. 30-34.
Bernini F, Soma MR, Corsini A, Paoletti R. Experimental and clinical effects of isradipine relevant to atherosclerosis. American Journal of Hypertension. 1994 Jul;7(7 PART 2):30-34.
Bernini, F. ; Soma, M. R. ; Corsini, A. ; Paoletti, R. / Experimental and clinical effects of isradipine relevant to atherosclerosis. In: American Journal of Hypertension. 1994 ; Vol. 7, No. 7 PART 2. pp. 30-34.
@article{2bb4c767e9544440b1ad154c4403d4f6,
title = "Experimental and clinical effects of isradipine relevant to atherosclerosis",
abstract = "A number of studies in experimental animal models have demonstrated the potential direct antiatherosclerotic effects of calcium antagonists. This class of compounds can influence several processes that are involved in the development of atherosclerotic lesions. This action is independent of either blood pressure reduction or hypercholesterolemia. A major problem encountered from the experimental data are the high doses used, which are several times higher than those used in the treatment of humans. One notable exception to this problem is the second-generation calcium antagonist isradipine, which exerts a direct antiatherosclerotic effect in rabbits at doses similar to those used in the clinic. Thus, this review is a summary of the effects and mechanisms of the antiatherosclerotic activity of isradipine.",
keywords = "atherogenesis, atherosclerosis, calcium antagonists, Isradipine",
author = "F. Bernini and Soma, {M. R.} and A. Corsini and R. Paoletti",
year = "1994",
month = "7",
language = "English",
volume = "7",
pages = "30--34",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "7 PART 2",

}

TY - JOUR

T1 - Experimental and clinical effects of isradipine relevant to atherosclerosis

AU - Bernini, F.

AU - Soma, M. R.

AU - Corsini, A.

AU - Paoletti, R.

PY - 1994/7

Y1 - 1994/7

N2 - A number of studies in experimental animal models have demonstrated the potential direct antiatherosclerotic effects of calcium antagonists. This class of compounds can influence several processes that are involved in the development of atherosclerotic lesions. This action is independent of either blood pressure reduction or hypercholesterolemia. A major problem encountered from the experimental data are the high doses used, which are several times higher than those used in the treatment of humans. One notable exception to this problem is the second-generation calcium antagonist isradipine, which exerts a direct antiatherosclerotic effect in rabbits at doses similar to those used in the clinic. Thus, this review is a summary of the effects and mechanisms of the antiatherosclerotic activity of isradipine.

AB - A number of studies in experimental animal models have demonstrated the potential direct antiatherosclerotic effects of calcium antagonists. This class of compounds can influence several processes that are involved in the development of atherosclerotic lesions. This action is independent of either blood pressure reduction or hypercholesterolemia. A major problem encountered from the experimental data are the high doses used, which are several times higher than those used in the treatment of humans. One notable exception to this problem is the second-generation calcium antagonist isradipine, which exerts a direct antiatherosclerotic effect in rabbits at doses similar to those used in the clinic. Thus, this review is a summary of the effects and mechanisms of the antiatherosclerotic activity of isradipine.

KW - atherogenesis

KW - atherosclerosis

KW - calcium antagonists

KW - Isradipine

UR - http://www.scopus.com/inward/record.url?scp=0028124424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028124424&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 30

EP - 34

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 7 PART 2

ER -